How Would a Ban on Prescriber-Identifying Information Impact Pharmaceutical Marketing?
Additional contact information
Doug Walker: Iowa State University, USA
International Journal of Public and Private Healthcare Management and Economics (IJPPHME), 2011, vol. 1, issue 3, 38-52
Recent legal proceedings have addressed pharmaceutical firmsâ€™ access to physician and brand level prescribing data. Proponents of the use of the data for marketing purposes claim constitutional protection as freedom of speech. Opponents maintain that distribution of the data compromises privacy. From the perspective of Granger-causality, this study investigates the extent to which pharmaceutical firms use this data to adjust detailing levels at the physician level. Important firm and public policy implications result. Consistent with the findings of previous work, detailing appears to Granger-cause prescription writing for a significant subset of physicians. However, the evidence that prescription writing Granger-causes adjustments in detailing levels is weak.
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://services.igi-global.com/resolvedoi/resolve. ... 8/ijpphme.2011070103 (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:igg:jpphme:v:1:y:2011:i:3:p:38-52
Access Statistics for this article
More articles in International Journal of Public and Private Healthcare Management and Economics (IJPPHME) from IGI Global
Bibliographic data for series maintained by Journal Editor ().